A message from the incoming editor

As you may know, I had the honor of beginning my service as incoming editor for Experimental and Clinical Psychopharmacology^® in January 2017. I have been handling new submissions since that date, but the journal remains under the watchful eye of the current editor, my friend and esteemed colleague, Suzette M. Evans, PhD, until the end of the year. Suzette has thoughtfully shepherded and ardently advocated for the journal over these past years, implementing innovations in the journal like increasing the focus on sex differences. This was an early adoption of an important trend that is now being seen in all of our National Institutes of Health (NIH) grant applications. Thank you, Suzette, for your service to the field and your support of my nascent editorship.

My goals for the journal are to maintain and increase its stature in the field, as well as to enhance the inclusiveness of the journal's audience, authors, reviewers and consulting editors. I'm only just starting down this road, but I'm excited to say that we have added more submission types for the journal, including brief reports, brief reviews and case reports, as a way to better engage a diverse audience. I'm also thrilled to have an outstanding group of consulting editors supporting the journals efforts. It is an engaged and influential group of early career and more seasoned investigators who will help to steer us towards success. The scope of the journal remains largely unchanged, but we have expanded the focus on sex differences started by Evans to include other relevant biological variables, given NIH's recent guidelines on these important factors. The scope was also edited to more strongly encourage submissions about experimental and clinical psychopharmacology research of all types (e.g., studies on the effects of antidepressants or anxiolytics), in addition to our already robust base of substance abuse related publications.

Information about the journal's scope, instructions for authors and consulting editors is available online.

I encourage you to become involved with the journal—submit a paper, sign up to be a reviewer or contact me about your interest in serving as a consulting editor. Experimental and Clinical Psychopharmacology closely aligns with the interests of Div. 28 and its members; it will be made stronger by your participation.